Divi’s Laboratories Ltd. is a leading Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and intermediates. The company was founded in 1990 and is headquartered in Hyderabad, Telangana, India. In this Article we will discuss about Divi’s Laboratories Share Price Target 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030.
Table of Contents
Introduction
Divi’s Laboratories has a strong presence in the global API market and is known for its high-quality products. It operates multiple manufacturing facilities that comply with international regulatory standards, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company’s manufacturing capabilities encompass a wide range of technologies, such as fermentation, chemical synthesis, and isolation.
The company’s product portfolio includes a diverse range of APIs used in various therapeutic categories, including anti-hypertensives, anti-ulceratives, anti-asthmatics, and antibiotics. Divi’s Laboratories has established a reputation for its commitment to research and development, investing significantly in advanced technology and innovative processes.
Business Model of Divi’s Laboratories Limited
The business model of Divi’s Laboratories revolves around the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and intermediates. Here are the key elements of their business model:
- API Development: Divi’s Laboratories focuses on the research and development of APIs, which are the key components of pharmaceutical drugs. They invest in advanced technology and innovative processes to develop high-quality APIs for various therapeutic categories.
- Manufacturing Excellence: Divi’s Laboratories operates multiple manufacturing facilities that adhere to stringent quality standards and regulatory requirements. They employ a range of manufacturing technologies, including fermentation, chemical synthesis, and isolation, to produce APIs and intermediates efficiently and in large quantities.
- Quality Assurance: Quality is a crucial aspect of Divi’s Laboratories’ business model. They have implemented robust quality assurance systems to ensure the consistent production of safe and effective APIs. Their manufacturing facilities comply with international regulatory standards, such as the US FDA and EMA, and undergo regular inspections to maintain compliance.
- Global Market Reach: Divi’s Laboratories has a strong global presence and exports its products to more than 95 countries. They have established long-term relationships with multinational pharmaceutical companies and generic drug manufacturers, serving as a reliable supplier of high-quality APIs. Their global market reach enables them to capitalize on diverse market opportunities.
- Customer Focus: Divi’s Laboratories prioritizes customer satisfaction and works closely with its clients to understand their specific requirements. They offer customized solutions, technical support, and timely delivery to meet the needs of their customers. This customer-centric approach helps them build strong and enduring partnerships.
- Formulation Development (Finished Dosage Forms): In addition to APIs, Divi’s Laboratories has expanded its business model to include the development and manufacturing of finished dosage forms. Through their subsidiary, Divi’s Laboratories USA Inc., they focus on developing and marketing finished dosage formulations for the US market, broadening their product offerings.
- Research and Development: Divi’s Laboratories emphasizes research and development activities to stay at the forefront of pharmaceutical innovation. They invest significantly in R&D to develop new processes, enhance existing products, and explore therapeutic areas for potential growth. Their commitment to R&D enables them to offer a competitive edge in the market.
Shareholding of Divi’s Laboratories Limited
| Shareholders Name | No. of Shares | %Shareholding |
| Total Share | 265468580 | 100% |
| Promoters | 342456428 | 51.94% |
| Foreign Institutions | 137883200 | 14.67% |
| Banks & Mutual Funds | 34910100 | 13.15% |
| Central Govt | 165 | 0.00% |
| Others | 7173011 | 2.7% |
| General Public | 25513808 | 9.61% |
| Financial Institutions | 21030859 | 7.92% |
Divi’s Laboratories Share
Divi’s Lab Share listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).
As of June 21, 2023, Divi’s Lab’s share price on the NSE was INR 3516/- Divi’s Lab Share 52 week high at Rs. 3973.90/- & 52 week low Rs.2730/-. The P/E Ratio of Divi’s Lab is 52.20.
| Company Name | Divi’s Laboratories Limited |
| Share Name | DIVISLAB |
| Sector | Pharma |
| Headquater | Hyderabad |
| Foundation | 1990 |
| Key Person | Kiran S Divi (MD & CEO) |
| Market Cap | 95,208.98 Crores Rs. |
| Revenue | 7,974.31 Crore Rs |
| Official Website | Click Here |
Divi’s Lab Share Price Target 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2040, 2050
| Year | First Target | Second Target |
| 2023 | 3620 | 3740 |
| 2024 | 3780 | 3950 |
| 2025 | 3990 | 4220 |
| 2026 | 4250 | 4530 |
| 2027 | 4580 | 4710 |
| 2028 | 4750 | 5030 |
| 2029 | 5070 | 5310 |
| 2030 | 5370 | 5750 |
| 2040 | 14700 | 15800 |
| 2050 | 34800 | 35900 |
Note:- “That these share price targets for “Divi’s Lab Share” are only provided for the purpose of reference and that this prediction will only hold true in the event that there is optimism in the market. Any uncertainties regarding the company or the current state of the global market will not be addressed in this analysis.”
Buy Divi’s Lab share in India’s Best Trading Platform @ 0 Rs. Brokerage
Annual Result Summary of Divi’s Laboratories Limited
Annual result summary of Divi’s Lab for 2022-23:
- Revenue: Consolidated total income declined by 10.7% to ₹8112 crore in FY23 from ₹9074 crore in FY22.
- Profit: Consolidated net profit declined by 39.3% to ₹1823 crore in FY23 from ₹2960 crore in FY22.
- EPS: EPS of Company is 68.11.
Last 5 Year Growth of Divi’s Laboratories Share
In Last 5 year Divi’s Lab Share give 236.23% returns to its Investors.
| Year | Share Price |
| June- 2019 | 1547.05 |
| June- 2020 | 2350.65 |
| June- 2021 | 4250.90 |
| June- 2022 | 3680.40 |
| June- 2023 | 3511.30 |
Divi’s Lab has grown significantly over the past 5 years, with a compound annual growth rate (CAGR) of 27.96%. However, the share price has declined in 2022, due to a number of factors, including the USFDA warning letter issued to the company’s formulation plant in Goa and the ongoing COVID-19 pandemic.
Here are some additional details about the 5-year growth of Divi’s Lab share:
- The highest closing share price was on 2021-09-01, at 3608.00 INR.
- The lowest closing share price was on 2018-01-23, at 1260.00 INR.
- The share price has traded above its 5-year average for most of the past 5 years.
- The share price is currently trading below its 5-year average.
Divi’s Laboratories Share Price Target 2023
Divis Laboratories primarily focuses on the production of APIs, which are the key components used in the manufacturing of finished pharmaceutical products. The company has expertise in complex chemistry and process development for APIs.
Divi’s Lab share price target 2023 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2023 | ₹3620 | ₹3740 |
Divi’s Laboratories Share Price Target 2024
The company has received multiple regulatory approvals from reputed authorities, including the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
Divi’s Lab share price target 2024 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2024 | ₹3780 | ₹3950 |
Divi’s Laboratories Share Price Target 2025
The company has a strong global presence and exports its products to over 95 countries worldwide. It has subsidiaries and representative offices in different regions, including the United States, Europe, Japan, and China.
Divi’s Lab share price target 2025 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2025 | ₹3990 | ₹4220 |
Divi’s Laboratories Share Price Target 2026
The company’s focus on research and development is crucial for its future growth. Divis Laboratories may invest in developing innovative processes and technologies, as well as exploring new drug delivery systems or formulations.
Divi’s Lab share price target 2026 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2026 | ₹4250 | ₹4530 |
Divi’s Laboratories Share Price Target 2027
Regulatory compliance will remain a significant aspect for Divis Laboratories. The company will need to stay updated with evolving regulations in different countries and ensure adherence to quality standards to maintain its global presence.
Divi’s Lab share price target 2027 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2027 | ₹4580 | ₹4710 |
Divi’s Laboratories Share Price Target 2028
Advancements in technology, such as automation, artificial intelligence, and data analytics, can enhance operational efficiency and manufacturing capabilities. Divis Laboratories may leverage these technologies to optimize processes, improve productivity, and reduce costs.
Divi’s Lab share price target 2028 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2028 | ₹4750 | ₹5030 |
Divi’s Laboratories Share Price Target 2029
The company’s growth may be influenced by factors such as changes in healthcare policies, market demand for APIs, and competition from other pharmaceutical companies. Expanding its footprint in emerging markets or strategic collaborations may be avenues for future growth.
Divi’s Lab share price target 2029 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2029 | ₹5070 | ₹5310 |
Divi’s Laboratories Share Price Target 2030
Divis Laboratories maintains a robust quality assurance system to ensure the safety, efficacy, and quality of its products. The company follows Good Manufacturing Practices (GMP) and other international quality standards.
Divi’s Lab share price target 2030 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2030 | ₹5370 | ₹5750 |
Dividend History of Divi’s Lab Share
Here is a brief overview of Divi’s dividend history over the past few years:
- In 2022, Company declared a final dividend of Rs.30 per share.
- In 2012, Company declared a final dividend of Rs.20 per share.
- In 2011, Company declared a final dividend of Rs.16 per share.
- In 2010, Company declared a final dividend of Rs.16 per share.
Joint venture & Subsidiaries of Divi’s Laboratories Limited
Divi’s Laboratories has established joint ventures and subsidiaries to expand its operations and market reach. Here are some notable joint ventures and subsidiaries of Divi’s Laboratories:
- Divi’s Laboratories USA Inc.: Divi’s Laboratories USA Inc. is a wholly-owned subsidiary of Divi’s Laboratories Ltd. It is based in New Jersey, USA, and focuses on the development and marketing of finished dosage formulations for the US market. This subsidiary enables Divi’s Laboratories to penetrate the US pharmaceutical market and cater to the specific requirements of the region.
- Divi’s Laboratories Europe BV: Divi’s Laboratories Europe BV is a subsidiary of Divi’s Laboratories Ltd. based in the Netherlands. It serves as a strategic hub for the company’s European operations, including sales, marketing, and distribution of APIs and intermediates. This subsidiary helps Divi’s Laboratories strengthen its presence and customer relationships in the European market.
- Laurus Labs Ltd.: Laurus Labs Ltd. is a joint venture between Divi’s Laboratories Ltd. and Aptuit Inc. (a subsidiary of Evotec AG). This joint venture focuses on providing integrated drug development services to global pharmaceutical companies. Laurus Labs offers services ranging from API development and manufacturing to formulation development and contract research.
- Neuland Laboratories Ltd.: Divi’s Laboratories holds a stake in Neuland Laboratories Ltd., an Indian pharmaceutical company that specializes in the manufacturing of APIs and intermediates. Neuland Laboratories is known for its quality and regulatory compliance and serves as a strategic partner for Divi’s Laboratories in meeting market demand.
Future Plan of Divi’s Laboratories
Divi’s Laboratories is a leading pharmaceutical company in India. It has a strong track record of growth and innovation, and is well-positioned for future growth. The company’s future plans include:
- Expanding its product portfolio. Divi’s Labs plans to expand its product portfolio by developing new APIs and finished dosages. The company is also looking to expand into new therapeutic areas, such as oncology and rare diseases.
- Investing in R&D. Divi’s Labs is committed to investing in R&D. The company has a strong R&D team that is constantly developing new products and technologies.
- Expanding its manufacturing capacity. Divi’s Labs is expanding its manufacturing capacity to meet the growing demand for its products. The company is building new plants in India and abroad.
- Entering new markets. Divi’s Labs is looking to enter new markets, such as the US and Europe. The company is already exporting its products to these markets, but it plans to increase its presence in these regions.
FAQs-
As of June 21, 2023, the current share price of Divi’s Lab is Rs 3,520.00.
For year 2023, Divi’s lab share price will be RS.3620/-
There are a few reasons why Divi’s Labs share price has been falling in recent months.
Weak quarterly results: The company’s quarterly results have been weak in recent quarters. In the first quarter of FY23, the company’s net profit fell by 24% year-on-year. This was due to a number of factors, including lower sales and margins.
Concerns about margin expansion: Investors are concerned about the company’s ability to expand margins in the future. The company’s margins have been under pressure in recent quarters due to rising input costs and competitive pricing.
Regulatory concerns: There are some regulatory concerns surrounding the company. In March 2023, the US FDA issued a warning letter to the company’s Kakinada plant. This letter raised concerns about the company’s manufacturing practices.
Macroeconomic headwinds: The global economy is facing some headwinds, which could impact the demand for the company’s products. These headwinds include rising inflation, interest rates, and economic uncertainty.
As per annual result of Divi’s Laboratories, the debt to equity ration of the company is 0%, so the company is debt free.
Traget Price of Divi’s lab share price will be RS.3620/- to Rs.3740./-
Future price of Divislab share is Rs.3620/-
